gw pharm

Title Article Datesort ascending Tags Notes
GW Pharma Reports Success with THC and CBD Combo in Brain Cancer Phase 2 Clinical Trial 02/08/2017 gw pharm, Studies, cancer
More Positive Results With Cannabidiol in Epilepsy 11/03/2015 Epidiolex, Studies, Orphan Study, gw pharm

More Positive Results With Cannabidiol in Epilepsy (You will need to google this title in order to get the article to avoid creating an account)
They found a reduction of the total number of seizures by a median of 38% at 3 months and 31% at 6 months.
These patients started on a cannabidiol (CBD) dose of 2 mg/kg per day, which was increased to a maximum tolerated dose or to 25 mg/kg per day.
Of the 25 patients enrolled in the study, two discontinued treatment before 6 months. One boy stopped medication after a few months because of intolerable diarrhea, and another patient discontinued the drug because of persistent nausea/vomiting. One patient didn't report 6-month data at the time of the analysis.
More than three quarters (77%) of the 22 remaining patients experienced fewer seizures after 6 months.
However, he stressed that the study was uncontrolled, symptoms were self-reported by families, and there has been a lot of news coverage of medical marijuana for the treatment of epilepsy. "Many parents had been avidly desirous of their child going on this cannabidiol because of what they had read in the lay press, so they were primed to believe this cannabidiol might be beneficial." On the other hand, he said, it's important to keep in mind that these children have "horrible epilepsy" and most have been on more than 10 medications for seizure without success. "Any improvement to that degree in this population that is sustained is a pretty dramatic response."
Cannabinoid Shows Positive Results in Treating Schizophrenia 09/15/2015 Schizophrenia, gw pharm, CBD

Positive top-line results have been reported from an exploratory phase 2a placebo-controlled clinical trial of cannabidiol (CBD, GW Pharmaceuticals) in patients with schizophrenia who had failed to respond adequately to first-line antipsychotic medications.  DOES NOT CONTAIN THC.
Liquid Medical Marijuana Shows Promise for Epilepsy 05/13/2015 epilepsy, gw pharm, Epidiolex

Among the 137 people who completed the study, the number of seizures fell by an average of 54 percent, according to a team led by Dr. Orrin Devinsky, of New York University Langone Comprehensive Epilepsy Center in New York City.
 Keep in mind that Epidiolex is VERY different than the so-called low THC strains of marijuana (also known as Charlotte’s Web) that are being grown and sold in several states.  Unlike Epidiolex, the strains of marijuana are  not cloned and the end products vary widely.  Most importantly, these strains contain varying levels of THC whereas Epidiolex is virtually pure CBD.
Medical Cannabis: Early Test Results Of Epidiolex Show Promise For Epilepsy Patients 05/03/2015 epilepsy, Epidiolex, gw pharm

.03%  or  93,200 children in the U.S. have severe forms of epilepsy and do not respond to current treatments of the population 320,000,000.  
 
Charlotte's Web results....Dr. Chapman and colleagues at Colorado Children’s Hospital and the University of Colorado reviewed cases of 58 children with severe epilepsy who came into their care while using artisanal CBD. Parents reported seizure reduction of 50% or more in only one-third of patients, but except for two children there was no improvement in their EEGs. Adverse effects occurred in 47% of patients: 21% experienced increased or new seizures; 10% suffered developmental regression with one patient needing intubation; one patient died.  
GW Pharmaceuticals Closes U.S. Public Offering; Cannabis-Based Medicines Progress 07/19/2014 Charlotte's Web, gw pharm, epilepsy
Comes Now Epidiolex™ (FDA approves IND studies of CBD) 10/22/2013 Epidiolex, Charlotte's Web, epilepsy, Dr. Guy, gw pharm
Subscribe to gw pharm